State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Current Cardiovascular Risk Reports

• Publication date

  2015-01-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12170-014-0430-5PMID 25844111PMCID PMC4382012
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel

  2016cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012.

  2014cited by this paper
• Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes.

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.

  2014cited by this paper
• Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation

  2014cited by this paper
• Predictors of adherence to performance measures in patients with acute myocardial infarction.

  2013influential reference
• ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

  2013cited by this paper
• The Relationship Between Metabolic Risk Factors and Incident Cardiovascular Disease in Europeans, South Asians, and African Caribbeans

  2013cited by this paper
• Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.

  2013cited by this paper
• Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome

  2013cited by this paper
• PHARMACODYNAMIC EFFECTS OF EV–077 IN PATIENTS WITH DIABETES MELLITUS ON CLOPIDOGREL MONOTHERAPY: RESULTS OF AN IN VITRO PILOT INVESTIGATION

  2013cited by this paper
• Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.

  2013cited by this paper
• Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis.

  2013cited by this paper
• Standards of Medical Care in Diabetes—2014

  2013cited by this paper
• Standards of Medical Care in Diabetes—2013

  2012cited by this paper
• Vorapaxar in the secondary prevention of atherothrombotic events.

  2012cited by this paper
• Relationship between post‐treatment platelet reactivity and ischemic and bleeding events at 1‐year follow‐up in patients receiving prasugrel

  2012cited by this paper
• Diabetes Mellitus and Trends in Hospital Survival After Myocardial Infarction, 1994 to 2006: Data From the National Registry of Myocardial Infarction

  2012cited by this paper
• A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

  2011cited by this paper
• Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications

  2011cited by this paper
• Variability of clopidogrel response in patients with type 2 diabetes mellitus

  2011cited by this paper
• Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.

  2011cited by this paper
• Globalization of Diabetes

  2011cited by this paper
• Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

  2011cited by this paper
• Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

  2011cited by this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cited by this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cited by this paper
• Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events.

  2010cited by this paper
• Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

  2010cited by this paper
• Use of oral antiplatelet agents in acute coronary syndromes

  2010cited by this paper
• Childhood Obesity – 2010: Progress and Challenges

  2010cited by this paper
• Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.

  2010cited by this paper
• Acute management of ACS Use of oral antiplatelet agents in acute coronary syndromes

  2010cited by this paper
• Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence

  2010cited by this paper
• Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes

  2010cited by this paper
• Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

  2010cited by this paper
• Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement

  2010cited by this paper
• Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus.

  2010cited by this paper
• Plasmepsin V licenses Plasmodium proteins for export into the host erythrocyte

  2009cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• Ticagrelor--is there need for a new player in the antiplatelet-therapy field?

  2009cited by this paper
• Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus.

  2009cited by this paper
• Factors Contributing to Increased Platelet Reactivity in People With Diabetes

  2009cited by this paper
• Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.

  2008cited by this paper
• Aspirin resistance associated with HbA1c and obesity in diabetic patients.

  2008cited by this paper
• The role of aspirin in cardiovascular prevention: implications of aspirin resistance.

  2008cited by this paper
• What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy?

  2008cited by this paper
• A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

  2008cited by this paper
• Letter by Klein Regarding Article, "Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results From the Aspirin-Induced Platelet Effect (ASPECT) Study"

  2008cited by this paper
• Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.

  2008cited by this paper
• Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.

  2008cited by this paper
• Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel.

  2008cited by this paper
• Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care

  2008cited by this paper
• Pharmacology of emerging novel platelet inhibitors.

  2008cited by this paper
• Impaired Fasting Glucose and Impaired Glucose Tolerance

  2007cited by this paper
• Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial

  2007cited by this paper
• Reticulated platelets and uninhibited COX‐1 and COX‐2 decrease the antiplatelet effects of aspirin

  2007cited by this paper
• Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population: National Health and Nutrition Examination Survey 1999–2002

  2007cited by this paper
• Platelet function monitoring in patients with coronary artery disease.

  2007cited by this paper
• Diabetes and mortality following acute coronary syndromes.

  2007cited by this paper
• Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.

  2007cited by this paper
• A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.

  2007cited by this paper
• Aspirin resistance and adverse clinical events in patients with coronary artery disease.

  2007cited by this paper
• Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study

  2007cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Standards of medical care in diabetes.

  2006cited by this paper
• Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment.

  2006cited by this paper
• Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population

  2006cited by this paper
• Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor

  2006cited by this paper
• Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus.

  2006cited by this paper
• Standards of Medical Care in Diabetes: Response to Power

  2006cited by this paper
• Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases

  2005cited by this paper
• Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.

  2005cited by this paper
• Low-dose aspirin increases aspirin resistance in patients with coronary artery disease.

  2005cited by this paper
• What is the best measure of thrombotic risks—pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?

  2005cited by this paper
• Prevalence of aspirin resistance in patients with type 2 diabetes

  2005cited by this paper
• Platelet Inhibition by Insulin Is Absent in Type 2 Diabetes Mellitus

  2005cited by this paper
• Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

  2004cited by this paper
• Platelet function testing in cardiovascular diseases.

  2004cited by this paper
• Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

  2004cited by this paper
• IRS-1 Mediates Inhibition of Ca2+ Mobilization by Insulin via the Inhibitory G-protein Gi*

  2004cited by this paper
• Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study.

  2004cited by this paper
• Soluble CD40 Ligand, Soluble P-Selectin, Interleukin-6, and Tissue Factor in Diabetes Mellitus: Relationships to Cardiovascular Disease and Risk Factor Intervention

  2004cited by this paper
• Lifetime risk for diabetes mellitus in the United States.

  2003cited by this paper
• The platelet in diabetes: focus on prevention of ischemic events.

  2003cited by this paper
• Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus.

  2003cited by this paper
• Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity

  2003cited by this paper
• Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.

  2002cited by this paper
• The pharmacology of cilostazol

  2002cited by this paper
• Inhibition of Platelet‐Collagen Interaction An In Vivo Action of Insulin Abolished by Insulin Resistance in Obesity

  2002cited by this paper
• Profile and prevalence of aspirin resistance in patients with cardiovascular disease.

  2001cited by this paper
• Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro

  2001cited by this paper
• Identification of the platelet ADP receptor targeted by antithrombotic drugs

  2001cited by this paper
• Oxidative stress in diabetic nephropathy: Basic and clinical information

  2001cited by this paper
• Platelet function in patients with familial hypertriglyceridemia: evidence that platelet reactivity is modulated by apolipoprotein E content of very-low-density lipoprotein particles.

  2000cited by this paper
• MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION

  2000cited by this paper
• Alterations in platelet Ca2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production

  1999cited by this paper
• In Vivo Formation of 8-Iso-Prostaglandin F2α and Platelet Activation in Diabetes Mellitus

  1999cited by this paper

• Evidence to action: significant cardiovascular health disparities among American racial and ethnic minorities

  2025cites this paper
• Diabetic Platelets: Pathophysiology, Clinical Significance, and Therapeutic Perspectives

  2025cites this paper
• Combining network pharmacology and bioinformatics to identify bioactive compounds and potential mechanisms of action of Sedum aizoon L in the treatment of atherosclerosis

  2023cites this paper
• Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention.

  2022cites this paper
• Cardiovascular Outcomes Observed with Ticagrelor versus Clopidogrel in Type 2 Diabetes Mellitus Patients with Acute Coronary Syndrome: A Meta-analysis

  2022cites this paper
• Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome

  2021cites this paper
• Impact of Diabetes on Platelet Function in Acute Ischemic Stroke Patients Taking Dual Antiplatelet Therapy

  2021cites this paper
• The correlation between platelet responsiveness to clopidogrel and CYP2C19 polymorphism in patients with peripheral vascular disease.

  2021cites this paper
• Impact of diabetes mellitus on outcomes of percutaneous coronary intervention in chronic total occlusions: A systematic review and meta-analysis.

  2021cites this paper
• Antiplatelet drugs and liver fibrosis

  2021cites this paper
• Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus

  2020cites this paper
• Role of platelet-derived growth factor in type II diabetes mellitus and its complications

  2020cites this paper
• The role of acetylsalicylic acid and circulating microRNAs in primary prevention of cardiovascular events in patients with Diabetes Mellitus Type 2 - A Review.

  2019cites this paper
• Platelets and Hemostasis

  2018cites this paper
• Gallic Acid Improves Health‐Associated Biochemical Parameters and Prevents Oxidative Damage of DNA in Type 2 Diabetes Patients: Results of a Placebo‐Controlled Pilot Study

  2018cites this paper
• Platelets and Diabetes

  2017cites this paper
• Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: A case-control study.

  2017cites this paper
• Induction of Diabetes Abolishes the Antithrombotic Effect of Clopidogrel in Apolipoprotein E–Deficient Mice

  2017cites this paper
• Aspirin and Clopidogrel Resistance in Coronary Artery Disease

  2017cites this paper
• Targeting aspirin resistance with nutraceuticals: a possible strategy for reducing cardiovascular morbidity and mortality

  2017cites this paper
• Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non–ST Elevation Myocardial Infarction: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry–Get with the Guideli

  2016cites this paper